Table 3.

Burst and cumulative release of BMP-2 from composite scaffolds in vitro and in vivo

		Phase 1 (%/day)		Phase 2 (%/day)		Phase 3 (%/day)		Phase 4 (%/day)
		PBS	Coll	PBS	Coll	PBS	Coll	PBS	Coll
In Vitro			^		^
	10 mM High	13.7 ± 3.6	26.9 ± 6.7*	3.6 ± 1.9	11.6 ± 1.7*	0.4 ± 0.0	1.2 ± 0.5*	0.7 ± 0.2	0.8 ± 0.4
	40 mM High	11.9 ± 4.9	17.8 ± 6.1	1.8 ± 0.6	7.4 ± 1.2*	0.3 ± 0.0	1.3 ± 0.2*	0.3 ± 0.1	0.5 ± 0.1
	PPF	56.3 ± 2.3^	56.7 ± 2.9	4.6 ± 0.7	4.9 ± 0.6	0.3 ± 0.0	0.3 ± 0.0^	0.2 ± 0.0	0.2 ± 0.0^
In Vivo
	10 mM High	21.2 ± 2.7		4.0 ± 2.4		1.2 ± 0.1		2.2 ± 0.1
	40 mM High	14.7 ± 0.7		5.0 ± 3.5		1.4 ± 0.8		1.8 ± 0.3
	PPF	55.1 ± 4.1^		8.2 ± 2.9		2.1 ± 0.5		0.3 ± 0.1^

Average percent values (% release per day) are given with standard deviations for n = 5–6 for in vitro groups and n = 3 for in vivo groups. Statistical significance (p<0.05) for gelatin crosslinking (10 mM, 40 mM, or PPF control scaffolds) is denoted by (^) and indicates significance for both comparisons with the other two groups. For buffer type (PBS vs. Coll), significance is noted by (*) (p<0.05).